A 32-Year-Old Man with Hepatitis C Who Developed Progressive Liver Failure after a Bone Marrow Transplant

Andre C. Lyra; Elizabeth M. Brunt; Steven Pincus; Adrian M. Di Bisceglie

doi:10.1055/s-2002-23211

Seminars in Liver Disease, Table of Contents

Semin Liver Dis 2002; 22(1): 103-108
DOI: 10.1055/s-2002-23211

DIAGNOSTIC PROBLEMS IN HEPATOLOGY

A 32-Year-Old Man with Hepatitis C Who Developed Progressive Liver Failure after a Bone Marrow Transplant

Andre C. Lyra¹ , Elizabeth M. Brunt² , Steven Pincus³ , Adrian M. Di Bisceglie¹

¹Division of Gastroenterology and Hepatology, Department of Internal Medicine, Saint Louis University School of Medicine, St. Louis, Missouri
²Department of Pathology, Saint Louis University School of Medicine, St. Louis, Missouri
³Division of Hematology and Oncology, Department of Internal Medicine, Saint Louis University School of Medicine, St. Louis, Missouri

Abstract

Full Text

References

REFERENCES

1 Sullivan K M, Deeg H J, Sanders J. Hyperacute graft-v-host disease in patients not given immunosuppression after allogeneic marrow transplantation. Blood . 1986; 67 1172-1175
2 Strasser S I, McDonald G B. Hepatobiliary complications of hematopoietic cell transplantation. In: Schiff ER, Sorrell MF, Maddrey WC, eds. Diseases of the Liver Philadelphia: Lippincott-Raven 1999: 1617-1641
3 Seeto R K, Fenn B, Rockey D C. Ischemic hepatitis: clinical presentation and pathogenesis. Am J Med . 2000; 109 109-113
4 Gibson P R, Dudley F J. Ischemic hepatitis: clinical features, diagnosis and prognosis. Aust N Z J Med . 1984; 14 822-825
5 Hautekeete M L, Kockx M M, Naegels S. Cholestatic hepatitis related to quinolones: a report of two cases. J Hepatol . 1995; 23 759-760
6 Sherman O, Beizer J L. Possible ciprofloxacin-induced acute cholestatic jaundice. Ann Pharmacother . 1994; 28 1162-1164
7 Contreras M A, Luna R, Mulero J, Andreu J L. Severe ciprofloxacin-induced acute hepatitis. Eur J Clin Microbiol Infect Dis . 2001; 20 434-435
8 Crerar-Gilbert A, Boots R, Fraenkel D, MacDonald G A. Survival following fulminant hepatic failure from fluconazole induced hepatitis. Anaesth Intensive Care . 1999; 27 650-652
9 Shulman H M, Hinterberger W. Hepatic veno-occlusive disease-liver toxicity syndrome after bone marrow transplantation. Bone Marrow Transplant . 1992; 10 197-214
10 Jones R J, Lee K S, Beschorner W E. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation . 1987; 44 778-783
11 Shulman H M, Fisher L B, Schoch H G. Veno-occlusive disease of the liver after marrow transplantation: histological correlates of clinical signs and symptoms. Hepatology . 1994; 19 1171-1181
12 DeLeve L D, McCuskey R S, Wang X. Characterization of a reproducible rat model of hepatic veno-occlusive disease. Hepatology . 1999; 29 1779-1791
13 Locasciulli A, Bacigalupo A, Alberti A. Predictability before transplant of hepatic complications following allogeneic bone marrow transplantation. Transplantation . 1989; 48 68-72
14 Shulman H M, McDonald G B, Matthews D. An analysis of hepatic venocclusive disease and centrilobular hepatic degeneration following bone marrow transplantation. Gastroenterology . 1980; 79 1178-1191
15 McDonald G B, Sharma P, Matthews D E. Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors Hepatology . 1984; 4 116-122
16 Frickhofen N, Wiesneth M, Jainta C. Hepatitis C virus infection is a risk factor for liver failure from veno-occlusive disease after bone marrow transplantation. Blood . 1994; 83 1998-2004
17 Strasser S I, Myerson D, Spurgeon C L. Hepatitis C virus infection and bone marrow transplantation: a cohort study with 10-year follow-up. Hepatology . 1999; 29 1893-1899
18 Azar N, Valla D, Abdel-Samad I. Liver dysfunction in allogeneic bone marrow transplantation recipients. Transplantation . 1996; 62 56-61
19 Locasciulli A, Bacigalupo A, Vanlint M T. Hepatitis C virus infection in patients undergoing allogeneic bone marrow transplantation. Transplantation . 1991; 52 315-318
20 Locasciulli A, Testa M, Valsecchi M G. The role of hepatitis C and B virus infections as risk factors for severe liver complications following allogeneic BMT: a prospective study by the Infectious Disease Working Party of the European Blood and Marrow Transplantation Group. Transplantation . 1999; 68 1486-1491
21 Barbaro G, Di Lorenzo G, Soldini M. Hepatic glutathione deficiency in chronic hepatitis C: quantitative evaluation in patients who are HIV positive and HIV negative and correlations with plasmatic and lymphocytic concentrations and with the activity of the liver disease. Am J Gastroenterol . 1996; 91 2569-2573
22 Vendemiale G, Grattagliano I, Portincasa P. Oxidative stress in symptom-free HCV carriers: relation with ALT flare-up. Eur J Clin Invest . 2001; 31 54-63
23 DeLeve L D. Cellular target of cyclophosphamide toxicity in the murine liver: role of glutathione and site of metabolic activation. Hepatology . 1996; 24 830-837
24 Moriya K, Nakagawa K, Santa T. Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis. Cancer Res . 2001; 61 4365-4370
25 De Maria N, Colantoni A, Fagiuoli S. Association between reactive oxygen species and disease activity in chronic hepatitis C Free Radic Biol Med . 1996; 21 291-295
26 Azoulay D, Castaing D, Lemoine A. Transjugular intrahepatic portosystemic shunt (TIPS) for severe veno-occlusive disease of the liver following bone marrow transplantation. Bone Marrow Transplant . 2000; 25 987-992
27 Fried M W, Connaghan D G, Sharma S. Transjugular intrahepatic portosystemic shunt for the management of severe venoocclusive disease following bone marrow transplantation. Hepatology . 1996; 24 588-591
28 Levy V, Azoulay D, Rio B. Successful treatment of severe hepatic veno-occlusive disease after allogeneic bone marrow transplantation by transjugular intrahepatic portosystemic stent-shunt (TIPS). Bone Marrow Transplant . 1996; 18 443-445
29 Morris J D, Harris R E, Hashmi R. Antithrombin-III for the treatment of chemotherapy-induced organ dysfunction following bone marrow transplantation. Bone Marrow Transplant . 1997; 20 871-878
30 Kulkarni S, Rodriguez M, Lafuente A. Recombinant tissue plasminogen activator (rtPA) for the treatment of hepatic veno-occlusive disease (VOD). Bone Marrow Transplant . 1999; 23 803-807
31 Partyka J, Kim J, Tate C. Hepatic Veno-Occlusive Disease: A Role for Tissue Plasminogen Activator?. Cancer Control . 1994; 1 248-251
32 Terra S G, Spitzer T R, Tsunoda S M. A review of tissue plasminogen activator in the treatment of veno-occlusive liver disease after bone marrow transplantation. Pharmacotherapy . 1997; 17 929-937
33 Patton D F, Harper J L, Wooldridge T N. Treatment of veno-occlusive disease of the liver with bolus tissue plasminogen activator and continuous infusion antithrombin III concentrate. Bone Marrow Transplant . 1996; 17 443-447